Organization
Instituto de Investigaciόn Hospital, Madrid, Spain
1 abstract
Abstract
ABP 501 BIOSMILAR TO ADALIMUMAB: FINAL SAFETY, IMMUNOGENICITY, AND EFFICACY RESULTS FROM AN OPEN-LABEL EXTENSION STUDY Org: Metroplex Clinical Research Center, Dallas, United States, Instituto de Investigaciόn Hospital, Madrid, Spain, Amgen, Thousand Oaks, United States of America, Abteilung für Nephrologie und Rheumatologie, Göttingen, Germany, Altoona Center for Clinical Research, Duncansville, United States,